An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease

AstraZeneca

Status: Completed

Conditions: GERD

Study type: Observational

Funder types: Industry

Identifiers

NCT01134367

NIS-GRS-DUM-2010/1

Details and patient eligibility

About

The purpose of this study is to examine patient's perspective of symptom control and impact of gastroesophageal reflux disease (GERD) on daily life.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with gastroesophageal reflux disease -GERD (disease duration ≤3 years or newly diagnosed) that are currently not treated with a proton pump inhibitor, for whom the general practitioner (GP) has previously decided to initiate or change the tre
• Patients should be treated for GERD according to current practice (National guideline for treatment of dyspepsia in GP setting)

Trial design

1,000 participants in 1 patient group

1

Description:

Patients with GERD